Embecta Corp. (NASDAQ:EMBC) Given Consensus Rating of “Strong Sell” by Analysts

Posted by Brenda Bartman on May 18th, 2026

Embecta Corp. (NASDAQ:EMBC – Get Free Report) has earned a consensus recommendation of “Strong Sell” from the five brokerages that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating and two have assigned a hold rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $11.00.

A number of research firms have recently issued reports on EMBC. Mizuho dropped their price objective on Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. BTIG Research cut Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Bank of America cut their price objective on Embecta from $11.00 to $3.00 and set an “underperform” rating for the company in a research report on Monday. Weiss Ratings lowered Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, May 6th. Finally, Zacks Research lowered Embecta from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th.

Check Out Our Latest Stock Analysis on Embecta

Embecta Trading Down 3.8%

NASDAQ EMBC traded down $0.12 on Monday, hitting $3.02. 1,986,623 shares of the company were exchanged, compared to its average volume of 1,334,032. The company has a market cap of $179.18 million, a PE ratio of 1.59 and a beta of 1.09. Embecta has a 12 month low of $2.99 and a 12 month high of $15.55. The stock has a fifty day moving average of $8.04 and a 200-day moving average of $10.60.

Embecta (NASDAQ:EMBC – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a net margin of 10.73% and a negative return on equity of 23.96%. The business had revenue of $221.80 million for the quarter, compared to analysts’ expectations of $235.67 million. During the same period in the prior year, the business earned $0.70 earnings per share. The company’s revenue for the quarter was down 14.4% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. On average, analysts expect that Embecta will post 1.58 earnings per share for the current year.

Embecta Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Thursday, May 28th will be given a $0.01 dividend. The ex-dividend date of this dividend is Thursday, May 28th. This represents a $0.04 dividend on an annualized basis and a yield of 1.3%. Embecta’s dividend payout ratio (DPR) is currently 31.58%.

Institutional Investors Weigh In On Embecta

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC lifted its stake in shares of Embecta by 368.6% during the third quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares in the last quarter. Wexford Capital LP bought a new position in shares of Embecta in the third quarter valued at $94,000. Tower Research Capital LLC TRC increased its holdings in shares of Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after buying an additional 6,224 shares in the last quarter. iSAM Funds UK Ltd bought a new position in shares of Embecta in the third quarter valued at $115,000. Finally, Neuberger Berman Group LLC bought a new position in shares of Embecta in the third quarter valued at $143,000. Hedge funds and other institutional investors own 93.83% of the company’s stock.

Embecta Company Profile

(Get Free Report)

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.